A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines

NCT07665996 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Spontaneous Urticaria (CSU)

Interventions

DRUG: TLL-018
DRUG: TLL-018
DRUG: Placebo

Sponsor

Hangzhou Highlightll Pharmaceutical Co., Ltd